June 1 (Reuters) - Antibe Therapeutics Inc ATE.V :
* ANTIBE THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B DOSE-RANGING, EFFICACY STUDY FOR ATB-346
* ANTIBE THERAPEUTICS - ATB-346 DEMONSTRATES SUPERIORITY TO PLACEBO IN REDUCING OSTEOARTHRITIS PAIN
* ANTIBE THERAPEUTICS INC - ATB-346 IS MORE POTENT THAN EXPECTED; LOWEST EFFECTIVE DOSE STILL TO BE ESTABLISHED
* ANTIBE THERAPEUTICS INC - PLANS PIVOTAL PHASE 2/3 ADAPTIVE REGISTRATION TRIAL
* ANTIBE THERAPEUTICS INC - ATB-346, MET PRIMARY ENDPOINT IN PHASE 2B DOSE-RANGING, EFFICACY STUDY
* ANTIBE THERAPEUTICS INC - ATB-346 WAS SAFE AND WELL TOLERATED DURING STUDY
* ANTIBE THERAPEUTICS - THERE WERE VERY FEW SERIOUS ADVERSE EVENTS OR EVENTS LEADING TO WITHDRAWAL OF TREATMENT IN STUDY